Nautilus Biotechnology, a Seattle-based startup, announced that it will go public via a special purpose acquisition (SPAC). Founded in 2016, Nautilus is building a combination of hardware and software to more accurately and efficiently quantify the human proteome. The company is working to change the way therapeutics are developed, seeking to catalyze a new wave of medical treatment. The special purpose acquisition marks the first step toward Nautilus eventually filing for an IPO.
Jeff Bezos-backed startup Nautilus Biotechnology set to go public via SPAC at $900M valuation